Late-Breaking KRYSTAL-7 data demonstrates
compelling efficacy and safety of adagrasib in combination with
pembrolizumab in 1L NSCLC
Data follows recent inclusion of
the adagrasib in combination with an EGFR inhibitor listed in
National Comprehensive Cancer Network (NCCN) Clinical Practice
Guidelines for Colon and Rectal Cancers
SAN
DIEGO, Sept. 27, 2023 /PRNewswire/ -- Mirati
Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage
research and development biotechnology company, today announced
several presentations to be unveiled at the European Society of
Medical Oncology Congress 2023 taking place October 20 to 24, 2023 in Madrid, Spain, including updated clinical data
showcasing the feasibility and potential of the investigational
combination of KRASG12C inhibitor, adagrasib with
pembrolizumab in a study of treatment naïve patients with advanced
non-small cell lung cancer (NSCLC) harboring a KRASG12C
mutation.
"Adagrasib is the first targeted KRASG12C
inhibitor to show promising efficacy and early signs of durability
in combination with an immune checkpoint inhibitor in the front
line setting," said Alan
Sandler, M.D. chief medical officer, Mirati Therapeutics.
"Based on this compelling data, we plan to initiate enrollment in a
global Phase 3 study in the fourth quarter evaluating
adagrasib in combination with pembrolizumab in patients with
KRAS G12C -mutated NSCLC with PD-L1 ≥50% with the hope
of providing a better treatment option for these patients."
Presentation Title: KRYSTAL-7: Efficacy and safety of
adagrasib with pembrolizumab in patients with treatment-naïve,
advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C
mutation
Author: Marina C.
Garassino
Abstract Number: 5053
Session: Proffered Paper session - NSCLC, metastatic
Presentation Date/Time: Fri, 10/20/23 16:40-16:50
CEST and 7:40-7:50 a.m.
PST
Presentation Title: Adagrasib With or Without Cetuximab
in Patients With KRASG12C-Mutated Colorectal Cancer
(CRC): Analysis of Tumor Biomarkers and Genomic Alterations
Author: Meredith S.
Pelster
Abstract Number: 3402
Session: Proffered Paper Session 1 – Gastrointestinal
tumours, lower digestive
Presentation Date/Time: Sat, 10/21/2023 15:25-15:35
CEST and 6:25-6:35 a.m.
PST
Presentation Title: SAPPHIRE: Phase 3 Study of
Sitravatinib Plus Nivolumab Versus Docetaxel in Patients With
Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer
(NSCLC)
Author: Hossein Borghaei
Abstract Number: 5049
Session: Proffered Paper session - NSCLC, metastatic
Presentation Date/Time: Fri, 10/20/23 16:00-16:10
CEST and 7:00-7:10 a.m.
PST
Symposium: Near the conclusion ESMO 2023, Mirati is
also sponsoring New Horizons in the Treatment of KRAS-Driven NSCLC
and GI Cancers, an industry satellite symposium with Luis Paz-Ares, M.D., Ph.D. of Hospital
Universitario 12 de Octubre, Aparna
Parikh, M.D. of Mass General Cancer Center, Harvard Medical School and Keith Kerr, MB ChB,
FRCPath, FRCPE of NHS Grampian. The symposium will discuss advances
in targeting KRAS-driven NSCLC with a focus on the current status
and future development of KRASG12C inhibitors, review the current
status of targeted therapies for GI cancers and discuss the
importance of timely molecular testing. The symposium will be held
on October 23 from 13:00-14:30 CEST in the Valencia Auditorium, Hall
10, IFEMA Madrid.
About Mirati Therapeutics, Inc.®
Mirati
Therapeutics, Inc. is a commercial stage research and development
biotechnology company whose mission is to discover, design and
deliver breakthrough therapies to transform the lives of patients
with cancer and their loved ones. The company is relentlessly
focused on bringing forward therapies that address areas of high
unmet need, including lung cancer, and advancing a pipeline of
novel therapeutics targeting the genetic and immunological drivers
of cancer. Unified for patients, Mirati's vision is to unlock the
science behind the promise of a life beyond cancer.
For more information about Mirati, visit us
at Mirati.com or follow us
on Twitter, LinkedIn and Facebook.
Forward Looking Statements
This press release includes
forward-looking statements regarding Mirati's business, financial
guidance and the therapeutic and commercial potential of
KRAZATI® (adagrasib), sitravatinib (TAM receptor
inhibitor), MRTX1719 (MTA-cooperative PRMT5 inhibitor), MRTX0902
(SOS1 inhibitor), and MRTX1133 (selective KRASG12D inhibitor),
Mirati's technologies and Mirati's other products in development.
Any statement describing Mirati's goals, expectations, intentions
or beliefs, financial or other projections, is a forward-looking
statement and should be considered an at-risk statement. Such
statements are subject to certain risks and uncertainties,
including those inherent in the process of discovering, developing
and commercializing medicines that are safe and effective for use
as human therapeutics, and in the endeavor of building a business
around such medicines.
Mirati's forward-looking statements also involve assumptions
that, if they never materialize or prove correct, could cause its
results to differ materially from those expressed or implied by
such forward-looking statements. Although Mirati's forward-looking
statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by
Mirati. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning
Mirati's programs are described in additional detail in Mirati's
annual report on Form 10-K, and most recent Form 10-Q, which are on
file with the Securities and Exchange Commission and available at
the SEC's Internet site (www.sec.gov). These forward-looking
statements are made as of the date of this press release, and
Mirati assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements,
except as required by law.
Mirati Contacts
Investor Relations: ir@mirati.com
Media Relations: media@mirati.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mirati-to-present-updated-clinical-data-at-esmo-congress-2023-301940962.html
SOURCE Mirati Therapeutics, Inc.